- Home
- ELLO vs NPCE Comparison
ELLO vs NPCE Comparison
Compare ELLO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$16.29
Company Overview
Basic Information| Metric | ELLO | NPCE |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.9M | 328.8M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELLO | NPCE |
|---|---|---|
| Price | $21.85 | $16.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.29 |
| AVG Volume (30 Days) | 3.7K | ★ 248.7K |
| Earning Date | 12-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $48,322,959.00 | ★ $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $1.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $13.00 | $7.56 |
| 52 Week High | $23.95 | $18.98 |
Technical Indicators
Market Signals| Indicator | ELLO | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 62.47 |
| Support Level | $21.82 | $16.00 |
| Resistance Level | $23.95 | $16.94 |
| Average True Range (ATR) | 0.81 | 0.80 |
| MACD | 0.12 | -0.11 |
| Stochastic Oscillator | 60.32 | 68.23 |
Price Performance
Historical Comparison ELLO
NPCE
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.